Jorge Miguel Ramos Perez
Biography
Jorge Miguel Ramos Perez, MD, is Assistant Clinical Professor in Hematopoietic Stem Cell Transplantation and Cellular Therapy at the University of California, Irvine. He received his Doctor of Medicine from Universidad Autonoma de Santo Domingo in the Dominican Republic and completed fellowship training in Stem Cell Transplant and Cellular Therapy at MD Anderson Cancer Center, followed by a Leukemia fellowship at MD Anderson and a Hematology/Oncology fellowship at City of Hope National Medical Center. He is currently pursuing a Master of Science in Applied Statistics from Pennsylvania State University.
Ramos Perez is board certified by the American Board of Internal Medicine, the American Board of Medical Oncology, and the American Board of Hematology. His clinical and research work focuses on acute myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia, and allogeneic hematopoietic cell transplantation. He received the Clinical Fellow of the Year award from the Leukemia Department at MD Anderson Cancer Center for the 2020-2021 academic year.
Ramos Perez has contributed to research examining prognostic factors in transplant outcomes, measurable residual disease monitoring in acute promyelocytic leukemia, and treatment approaches for patients with acute myeloid leukemia and chronic myelomonocytic leukemia. He has authored book chapters on the treatment of older patients with acute myeloid leukemia who are ineligible for intensive chemotherapy and has presented research on geriatric complications following allogeneic hematopoietic cell transplantation in older adults.
Return to topEducation
- M.D., Universidad Autonoma de Santo Domingo - Dominican Republic, 2008
- M.S. in Applied Statistics, Pennsylvania State University (Penn State), 2026
Distinctions
- Clinical Fellow of the Year, Leukemia Department, MD Anderson Cancer Center, 2020-2021
Areas of Expertise
- Hematologic Malignancies and Transplantation
- Acute Myeloid Leukemia Therapy
- Chronic Myelomonocytic Leukemia Management
- Hypomethylating Agent Combinations
- Geriatric Complications Post-Transplant
- Transplantation-Associated Thrombotic Microangiopathy
- Haploidentical Donor Transplantation
Recent Publications
- Lee B.J., Griffin S.P., Doh J., Quach A., Sun Y., Chumnumsiriwath P., Ciurea S.O., Ramos-Perez J., Bellman P., Jeyakumar D., Kongtim P., Naqvi K., “Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia” (opens in new tab), British Journal of Haematology, vol. 208, pp. 570-578, 2026.
- Chumnumsiriwath P, Vittayawacharin P, Ramos-Perez J, Jeyakumar D, Lee BJ, Doh J, Griffin S, Nguyen M, Hanna RM, Tran MH, Kongtim P, Ciurea SO, “Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT)” (opens in new tab), Bone Marrow Transplantation, vol. 60, pp. 1065-1069, 2025.
- Griffin SP, Lee BJ, Chumnumsiriwath P, Kim Sharon, Doh J, Jeyakumar D, Ramos-Perez J, Kongtim P, Ciurea SO, “Early Initiation of Tacrolimus Prior to Post-Transplant Cyclophosphamide in Peripheral Blood Haploidentical Transplantation”, Transplantation and Cellular Therapy, vol. 31, no. 2, Supplement, pp. S544, 2025.
- Bhandari R, Shan H, Ramos-Perez J, Sitong C, Bosworth A, Yang D, Al Malki MM, Dale W, Forman SJ, Nakamura R, Wong L, Armenian SH, Artz A, “The Influence of Race/Ethnicity and Social Vulnerability on Non-Relapse Mortality after Transplant in Older (>60 Years) Adults”, Transplantation and Cellular Therapy, vol. 31, no. 2, Supplement, pp. S436-S437, 2025.
- Shimony S., Bewersdorf J.P., Shallis R.M., Liu Y., Schaefer E.J., Zeidan A.M., Goldberg A.D., Stein E.M., Marcucci G., Lindsley R.C., Chen E.C., Ramos Perez J., Stein A., DeAngelo D.J., Neuberg D.S., Stone R.M., Ball B., Stahl M., “Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML” (opens in new tab), Leukemia, vol. 38, pp. 762-768, 2024.
- Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, et al., “Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy” (opens in new tab), Leukemia and Lymphoma, vol. 63, no. 2, pp. 672-675, 2022.
- Ramos Perez JM, Shan H, Yang D, Cabrera Chien L, Uranga C, Salman J, “Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)”, Blood, vol. 140, no. Supplement 1, pp. 7574-5, 2022.
- Ramos Perez JM, Tinajero J, Ngo D, Zhang J, Koller PB, Agrawal V, “Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy”, Blood, vol. 140, no. Supplement 1, pp. 9039-40, 2022.
- Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, et al., “Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia” (opens in new tab), American Journal of Hematology, vol. 96, no. 1, pp. E50-E53, 2021.
- Montalban-Bravo G., Hammond D., DiNardo C.D., Konopleva M., Borthakur G., Short N.J., Ramos-Perez J., Guerra V., Kanagal-Shamanna R., Naqvi K., Sasaki K., Jabbour E., Pemmaraju N., Kadia T.M., Ravandi F., Daver N., Estrov Z., Pierce S., Kantarjian H., Garcia-Manero G., “Activity of venetoclax-based therapy in chronic myelomonocytic leukemia” (opens in new tab), Leukemia, vol. 35, pp. 1494-1499, 2021.
- Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SO, “Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation” (opens in new tab), Biology of Blood and Marrow Transplantation, vol. 26, no. 1, pp. 197-203, 2020.
- Ciurea SO, Kongtim P, Hasan O, Ramos Perez JM, Torres J, Rondon G, Champlin RE, “Validation of a Hematopoietic Cell Transplant-Composite Risk (HCT-CR) Model for Post-Transplant Survival Prediction in Patients with Hematologic Malignancies” (opens in new tab), Clinical Cancer Research, vol. 26, no. 10, pp. 2404-2410, 2020.
- Ramos Perez J, Ravandi-Kashani F, “The pharmacological management of hairy cell leukemia” (opens in new tab), Expert Opinion on Pharmacotherapy, vol. 21, no. 11, pp. 1337-1344, 2020.
- Ramos Perez J, Montalban-Bravo G, “Emerging drugs for the treatment of chronic myelomonocytic leukemia” (opens in new tab), Expert Opinion on Emerging Drugs, vol. 25, no. 4, pp. 515-529, 2020.
- Ramos Perez JM, Guerra VA, Hammond D, Chien KS, Kanagal-Shamanna R, Naqvi K, “Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories”, Blood, vol. 136, no. Supplement 1, pp. 8-9, 2020.
- Guerra V, Ramos Perez JM, Hammond D, Chien KS, Kanagal-Shamanna R, Naqvi K, “Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure”, Blood, vol. 136, no. Supplement 1, pp. 22-3, 2020.
- Guerra VA, Alwash Y, Yuanqing Y, Ramos Perez JM, Richard-Carpentier G, Alotaibi AS, “Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Myeloid Leukemia (AML)”, Blood, vol. 136, no. Supplement 1, pp. 29-30, 2020.
- Hammond D, DiNardo CD, Konopleva M, Borthakur G, Ramos Perez JM, Guerra VA, “Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation”, Blood, vol. 136, no. Supplement 1, pp. 36-7, 2020.
This profile was created with the help of AI.
Last updated on 5/19/2026.